Abstract Number: 98 • 2018 ACR/ARHP Annual Meeting
Presence of Apoptotic Microparticle Containing Immune Complexes in Asymptomatic ANA+ Individuals Despite the Absence of Inflammation
Background/Purpose: Currently, little is known about what distinguishes asymptomatic Anti-Nuclear Antibody (ANA) positive individuals (ANA+NS) who will progress to Systemic Lupus Erythematosus (SLE) from those…Abstract Number: 110 • 2018 ACR/ARHP Annual Meeting
Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways
Background/Purpose: One hallmark of the autoimmune disease Systemic lupus erythematosus (SLE) is the presence of antinuclear antibodies (ANAs). While the specificities and levels can indicate…Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…Abstract Number: 758 • 2018 ACR/ARHP Annual Meeting
Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence…Abstract Number: 1188 • 2018 ACR/ARHP Annual Meeting
Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic
Background/Purpose: A positive anti-nuclear antibody (ANA) is considered very useful for the diagnosis of SLE and systemic sclerosis, and somewhat useful for the diagnosis of…Abstract Number: 43 • 2017 ACR/ARHP Annual Meeting
Regulation of TLR7 Signalling By UBE2L3 Dependent Linear Ubiquitination Explains Dimethyl Fumarate Suppression of Autoreactive B Cell Development in SLE
Background/Purpose: A single risk haplotype spanning UBE2L3 is strongly associated with SLE and multiple autoimmune diseases. The E2 ubiquitin-conjugating enzyme UBE2L3 regulates TNFα and CD40…Abstract Number: 198 • 2017 ACR/ARHP Annual Meeting
The Impact of Electronic Consults (E-Consults) on Positive ANA Referrals in a Veteran Population
Background/Purpose: Referrals to rheumatology for positive ANA in the absence of clinical signs and symptoms is a common practice, which may lead to unnecessary resource…Abstract Number: 476 • 2017 ACR/ARHP Annual Meeting
Novel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) display broad cross-reactivities and target proteins including a-enolase, filaggrin, vimentin, fibrinogen, and histones. However, every monoclonal ACPA has a distinct…Abstract Number: 559 • 2017 ACR/ARHP Annual Meeting
Performance of Multiple Platforms for Autoantibody Testing in Sjogren’s Syndrome
Background/Purpose: The research classification and clinical diagnosis of SjšgrenÕs syndrome (SS) relies heavily on the detection of autoantibodies against Ro/SSA and La/SSB, particularly in the…Abstract Number: 673 • 2017 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement
Background/Purpose: Patients are often referred to the rheumatologist because of elevated anti-nuclear antibody (ANA) titers. We sought to evaluate the association of cell bound complement…Abstract Number: 700 • 2017 ACR/ARHP Annual Meeting
Variability in Method of Testing for Antinuclear Antibodies (ANA): A Survey of Participants in the College of American Pathologist’s (CAP) Proficiency Testing Program
Background/Purpose: A 2010 American College of Rheumatology position paper designated indirect immunofluorescence assay (IFA) on HEp-2 cells the “gold standard” for ANA testing and that…Abstract Number: 1097 • 2017 ACR/ARHP Annual Meeting
Investigating Opportunities for Cost Conscious Care: A Review of Physician Practice in Ordering Anti-Nuclear Antibody Testing at an Academic Community Hospital
Background/Purpose: More than 94,000 ANA tests are performed each year resulting in an estimated cost of 2.24 million dollars annually. The American College of Rheumatology…Abstract Number: 2578 • 2017 ACR/ARHP Annual Meeting
RAB4A Protects from Antinuclear Antibody Production and Nephritis in the Pristane-Induced Model of SLE
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease characterized by circulating antinuclear autoantibodies and dysfunction of B cells, T cells, and dendritic…Abstract Number: 2918 • 2016 ACR/ARHP Annual Meeting
The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis
Background/Purpose: Antinuclear antibody (ANA) test is positive in nearly 95% of patients with systemic sclerosis (SSc) [1]. We aim to identify the clinical relevance of…Abstract Number: 443 • 2016 ACR/ARHP Annual Meeting
Repetitive Requisition of Antinuclear Antibody Testing (ANA) in Outpatient Multispecialty Clinics in Patients with a Known Positive ANA
Background/Purpose: Methods: Retrospective chart review was performed on 598 patients who underwent ANA testing between April 1st, 2015 and March 31st, 2016. Data collected…